Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IDRA

Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis

Idera Pharmaceuticals logo

About Idera Pharmaceuticals Stock (NASDAQ:IDRA)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.17
$7.23
52-Week Range
N/A
Volume
21,870 shs
Average Volume
464,030 shs
Market Capitalization
$450.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IDRA Stock News Headlines

Ekso Bionics (NASDAQ: EKSO)
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
Kiniksa Pharmaceuticals
Nabriva Therapeutics AG (NBRVF)
Marginalia
See More Headlines

IDRA Stock Analysis - Frequently Asked Questions

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01.

Idera Pharmaceuticals shares split on the morning of Friday, November 25th 2022.The 2-1 split was announced on Friday, November 25th 2022. The newly issued shares were distributed to shareholders after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Idera Pharmaceuticals investors own include BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Sorrento Therapeutics (SRNE), Proteostasis Therapeutics (PTI), Dynavax Technologies (DVAX), Agenus (AGEN) and SCYNEXIS (SCYX).

Company Calendar

Last Earnings
11/08/2021
Today
8/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IDRA
CIK
861838
Employees
32
Year Founded
1989

Profitability

EPS (Trailing Twelve Months)
($0.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$98.09 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-68.74%
Return on Assets
-34.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.56
Quick Ratio
1.56

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
0.29
Book Value
$0.56 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
62,355,000
Free Float
59,206,000
Market Cap
$450.52 million
Optionable
Optionable
Beta
1.25

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:IDRA) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners